Journal
JOURNAL OF MEDICAL GENETICS
Volume 44, Issue 3, Pages 166-172Publisher
BMJ PUBLISHING GROUP
DOI: 10.1136/jmg.2006.046102
Keywords
-
Categories
Ask authors/readers for more resources
Frequent overexpression of epidermal growth factor receptor ( EGFR) in non-small-cell lung cancer (NSCLC) makes EGFR a new therapeutic target. Two specific EGFR tyrosine kinase inhibitors, gefitinib (ZD1839, Iressa) and erlotinib (OSI-774, Tarceva), have been developed and approved by the US Food and Drug Administration for second-line and third-line treatment of advanced NSCLC. Clinical trials have shown considerable variability in the response rate between different patients with NSCLC, which led to the discovery of somatic EGFR-activating mutations. This brief review summarises the discovery and functional consequences of the mutations, their clinicopathological features and significant implications in the treatment and prognosis of NSCLC.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available